

# Elli Papaemmanuil

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7999448/publications.pdf>

Version: 2024-02-01

128  
papers

31,030  
citations

26567

56  
h-index

17546

121  
g-index

141  
all docs

141  
docs citations

141  
times ranked

40566  
citing authors

#	ARTICLE	IF	CITATIONS
1	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	13.7	8,060
2	Genomic Classification and Prognosis in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 2209-2221.	13.9	3,067
3	Mutational Processes Molding the Genomes of 21 Breast Cancers. <i>Cell</i> , 2012, 149, 979-993.	13.5	1,673
4	Clinical and biological implications of driver mutations in myelodysplastic syndromes. <i>Blood</i> , 2013, 122, 3616-3627.	0.6	1,562
5	The landscape of cancer genes and mutational processes in breast cancer. <i>Nature</i> , 2012, 486, 400-404.	13.7	1,535
6	The Life History of 21 Breast Cancers. <i>Cell</i> , 2012, 149, 994-1007.	13.5	1,249
7	The evolutionary history of lethal metastatic prostate cancer. <i>Nature</i> , 2015, 520, 353-357.	13.7	1,185
8	Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts. <i>New England Journal of Medicine</i> , 2011, 365, 1384-1395.	13.9	1,094
9	Prediction of acute myeloid leukaemia risk in healthy individuals. <i>Nature</i> , 2018, 559, 400-404.	13.7	617
10	Effect of Mutation Order on Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2015, 372, 601-612.	13.9	467
11	Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2011, 118, 6239-6246.	0.6	457
12	Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2009, 41, 1006-1010.	9.4	445
13	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2018, 379, 1416-1430.	13.9	442
14	Clinical significance of somatic mutation in unexplained blood cytopenia. <i>Blood</i> , 2017, 129, 3371-3378.	0.6	379
15	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	15.2	372
16	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	9.4	367
17	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. <i>Blood</i> , 2015, 126, 233-241.	0.6	361
18	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. <i>Nature Genetics</i> , 2013, 45, 18-24.	9.4	359

#	ARTICLE	IF	CITATIONS
19	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014, 345, 1251343.	6.0	348
20	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. <i>ELife</i> , 2014, 3, .	2.8	318
21	RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2014, 46, 116-125.	9.4	313
22	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. <i>Blood</i> , 2017, 130, 732-741.	0.6	300
23	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
24	Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. <i>Nature Genetics</i> , 2014, 46, 487-491.	9.4	254
25	Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. <i>Nature Genetics</i> , 2010, 42, 492-494.	9.4	248
26	Whole exome sequencing of adenoid cystic carcinoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 2965-2968.	3.9	233
27	Precision oncology for acute myeloid leukemia using a knowledge bank approach. <i>Nature Genetics</i> , 2017, 49, 332-340.	9.4	229
28	Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. <i>Blood</i> , 2014, 124, 1513-1521.	0.6	222
29	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. <i>Nature Communications</i> , 2015, 6, 5901.	5.8	196
30	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , 2019, 33, 1747-1758.	3.3	195
31	<i>SF3B1</i> -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020, 136, 157-170.	0.6	195
32	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. <i>Nature Medicine</i> , 2018, 24, 1867-1876.	15.2	179
33	Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. <i>Blood</i> , 2018, 132, 1225-1240.	0.6	168
34	Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. <i>Nature Immunology</i> , 2015, 16, 766-774.	7.0	163
35	Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. <i>Blood</i> , 2010, 115, 1765-1767.	0.6	142
36	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018, 32, 2604-2616.	3.3	137

#	ARTICLE	IF	CITATIONS
37	Genomic Classification in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 900-901.	13.9	134
38	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood</i> , 2019, 134, 1498-1509.	0.6	123
39	Subclonal variant calling with multiple samples and prior knowledge. <i>Bioinformatics</i> , 2014, 30, 1198-1204.	1.8	122
40	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. <i>Blood</i> , 2015, 125, 499-503.	0.6	115
41	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. <i>Cell Stem Cell</i> , 2017, 20, 315-328.e7.	5.2	114
42	Inactivating CUX1 mutations promote tumorigenesis. <i>Nature Genetics</i> , 2014, 46, 33-38.	9.4	111
43	Single-cell mutational profiling and clonal phylogeny in cancer. <i>Genome Research</i> , 2013, 23, 2115-2125.	2.4	105
44	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. <i>Blood Advances</i> , 2020, 4, 1131-1144.	2.5	102
45	Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. <i>Cell Reports</i> , 2017, 20, 572-585.	2.9	99
46	Timing the initiation of multiple myeloma. <i>Nature Communications</i> , 2020, 11, 1917.	5.8	99
47	Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. <i>Cancer Cell</i> , 2019, 36, 123-138.e10.	7.7	93
48	Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. <i>Journal of Experimental Medicine</i> , 2019, 216, 966-981.	4.2	91
49	The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. <i>Leukemia</i> , 2013, 27, 889-896.	3.3	89
50	Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. <i>JCI Insight</i> , 2017, 2, .	2.3	89
51	Processed pseudogenes acquired somatically during cancer development. <i>Nature Communications</i> , 2014, 5, 3644.	5.8	86
52	Revealing the Impact of Structural Variants in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2020, 1, 258-273.	2.6	81
53	Clonal hematopoiesis is associated with risk of severe Covid-19. <i>Nature Communications</i> , 2021, 12, 5975.	5.8	81
54	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015, 25, 814-824.	2.4	69

#	ARTICLE	IF	CITATIONS
55	SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. <i>Blood</i> , 2017, 130, 881-890.	0.6	66
56	Single cell analysis of clonal architecture in acute myeloid leukaemia. <i>Leukemia</i> , 2019, 33, 1113-1123.	3.3	65
57	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. <i>Nature Communications</i> , 2021, 12, 338.	5.8	64
58	Managing Clonal Hematopoiesis in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 7-11.	0.8	60
59	Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors. <i>Cancer Cell</i> , 2018, 33, 274-291.e8.	7.7	58
60	Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. <i>Haematologica</i> , 2013, 98, 420-423.	1.7	51
61	Characterisation of the genomic landscape of <i>CRLF2</i> -rearranged acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 363-372.	1.5	49
62	Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 37-44.	0.9	49
63	PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. <i>Blood Advances</i> , 2018, 2, 3526-3539.	2.5	42
64	The Clinical Management of Clonal Hematopoiesis. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 357-367.	0.9	42
65	Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020, 11, 3617.	5.8	41
66	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 101.	2.8	40
67	Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. <i>Blood</i> , 2019, 134, 2195-2208.	0.6	39
68	Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. <i>Leukemia</i> , 2020, 34, 1476-1480.	3.3	39
69	Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in <i>SF3B1</i> mutated refractory anaemia with ring sideroblasts. <i>British Journal of Haematology</i> , 2015, 171, 478-490.	1.2	37
70	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. <i>Blood Advances</i> , 2017, 1, 1911-1918.	2.5	37
71	Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk. <i>Blood</i> , 2010, 115, 4472-4477.	0.6	36
72	Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer. <i>Cell Reports</i> , 2016, 16, 2032-2046.	2.9	36

#	ARTICLE	IF	CITATIONS
73	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. <i>Acta Neuropathologica</i> , 2021, 142, 841-857.	3.9	36
74	A recurrent novel <i>MGA</i> – <i>NUTM1</i> fusion identifies a new subtype of high-grade spindle cell sarcoma. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a003194.	0.5	32
75	Successful Targeted Therapy of Refractory Pediatric <i>ETV6-NTRK3</i> Fusion-Positive Secretory Breast Carcinoma. <i>JCO Precision Oncology</i> , 2017, 2017, 1-8.	1.5	31
76	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. <i>ELife</i> , 2019, 8, .	2.8	31
77	Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. <i>Nature Communications</i> , 2022, 13, 2485.	5.8	31
78	Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. <i>Blood Cancer Journal</i> , 2019, 9, 15.	2.8	30
79	Isabl Platform, a digital biobank for processing multimodal patient data. <i>BMC Bioinformatics</i> , 2020, 21, 549.	1.2	26
80	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. <i>Leukemia</i> , 2022, 36, 625-636.	3.3	25
81	MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2011, 117, 1633-1640.	0.6	24
82	Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. <i>PLoS ONE</i> , 2019, 14, e0211600.	1.1	24
83	11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. <i>Cancer</i> , 2020, 126, 3114-3121.	2.0	23
84	Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 1364-1373.	2.0	22
85	Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression. <i>Genome Medicine</i> , 2019, 11, 86.	3.6	20
86	<i>ZBTB33</i> Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing. <i>Blood Cancer Discovery</i> , 2021, 2, 500-517.	2.6	17
87	The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. <i>Blood Reviews</i> , 2021, 46, 100744.	2.8	16
88	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. <i>Molecular Cancer Research</i> , 2021, 19, 1146-1155.	1.5	14
89	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 132-141.	1.1	12
90	Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <i>AKT1</i> Fusion–Driven Cancer. <i>Cancer Discovery</i> , 2019, 9, 605-616.	7.7	11

#	ARTICLE	IF	CITATIONS
91	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal <i>SDHB</i> -Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	9
92	Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment. <i>Blood Cancer Journal</i> , 2020, 10, 76.	2.8	9
93	Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3 <sup>+</sup> T cells represents a potential antitumor mechanism of azacitidine. <i>Blood Advances</i> , 2021, 5, 129-142.	2.5	7
94	Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 4003-4011.	3.2	7
95	Association of <i>BRAF V600E</i> mutations with vasoactive intestinal peptide syndrome in <i>MYCN</i> -amplified neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29265.	0.8	7
96	<i>IKZF1</i> alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial. <i>Blood Advances</i> , 2021, 5, 3322-3332.	2.5	7
97	Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of <i>SF3B1</i> -mutant HSPCs. <i>Blood Advances</i> , 2022, 6, 2992-3005.	2.5	7
98	Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 991.e1-991.e9.	0.6	6
99	Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14. <i>Blood</i> , 2019, 134, 288-288.	0.6	6
100	Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling. <i>Blood</i> , 2019, 134, 1392-1392.	0.6	6
101	Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q). <i>Leukemia</i> , 2022, 36, 1436-1439.	3.3	6
102	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. <i>Clinical Cancer Research</i> , 2021, 27, 2111-2118.	3.2	5
103	Revealing the Impact of Recurrent and Rare Structural Variations in Multiple Myeloma. <i>Blood</i> , 2019, 134, 576-576.	0.6	5
104	Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 1614-1627.	3.2	4
105	Identification of Novel Somatic Mutations in <i>SF3B1</i> , a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts and Other Common Cancers. <i>European Journal of Cancer</i> , 2011, 47, 7.	1.3	3
106	Capture Rate of the Adaptive Next Generation Sequencing VDJ Assay in Multiple Myeloma. <i>Blood</i> , 2018, 132, 3184-3184.	0.6	3
107	Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3277-3281.	0.6	2
108	Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials. <i>Blood</i> , 2018, 132, 664-664.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2160-2166.	3.2	2
110	Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials. <i>Blood</i> , 2019, 134, 2746-2746.	0.6	1
111	Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies. <i>Blood</i> , 2019, 134, 913-913.	0.6	1
112	Whole Genome Sequencing of Extramedullary Myeloma Autopsy Tumors Reveals a Genomic Portrait at Culmination of Clonal Convergence. <i>Blood</i> , 2018, 132, 3169-3169.	0.6	1
113	Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 292-292.	0.6	1
114	Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome. <i>Blood</i> , 2018, 132, 543-543.	0.6	1
115	Targeted Sequencing Predicts the Development of Myeloid Malignancies and Clinical Outcome in Patients with Unexplained Cytopenia. <i>Blood</i> , 2019, 134, 1712-1712.	0.6	1
116	Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients. <i>Blood</i> , 2020, 136, 37-38.	0.6	1
117	Germline Contributions to Clonal Hematopoiesis in Solid Cancer Patients. <i>Blood</i> , 2020, 136, 30-31.	0.6	1
118	PHF6 Mutations Are Mutually Exclusive to TP53 Mutations, and Define a Distinct Subgroup of Secondary Acute Myeloid Leukemia Associated with a Primitive Stem/Progenitor Immunophenotype, Absent Complex Karyotype and Relatively Better Outcomes. <i>Blood</i> , 2018, 132, 2788-2788.	0.6	0
119	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. <i>Blood</i> , 2018, 132, 5241-5241.	0.6	0
120	V(D)J Sequence Capture for DNA-Based Minimal Residual Disease Detection in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4444-4444.	0.6	0
121	Mytype: A Capture Based Sequencing Approach to Detect Somatic Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma. <i>Blood</i> , 2018, 132, 5588-5588.	0.6	0
122	Timing the Initiation of Multiple Myeloma. <i>Blood</i> , 2019, 134, 573-573.	0.6	0
123	Molecular Characteristics That Predict Response to Azacitidine Therapy. <i>Blood</i> , 2019, 134, 4246-4246.	0.6	0
124	Isogenic MDS-RS Patient-Derived iPSCs Define the Mis-Spliced Transcript Repertoire and Chromatin Landscape of SF3B1-Mutant Hematopoietic Stem/Progenitor Cells. <i>Blood</i> , 2021, 138, 147-147.	0.6	0
125	Whole Transcriptome Analysis Identifies Distinct Gene Expression Profiles between SF3B1mut and SF3B1 wt Myelodysplastic Syndrome with Ring Sideroblasts. <i>Blood</i> , 2021, 138, 3695-3695.	0.6	0
126	<i>Post-Treatment Clone Size Predicts Survival Independently of IPSS-R and Response after Azacitidine Therapy for MDS.</i>. <i>Blood</i> , 2020, 136, 12-13.	0.6	0



#	ARTICLE	IF	CITATIONS
127	Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis. <i>Blood</i> , 2020, 136, 29-30.	0.6	0
128	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. <i>Blood</i> , 2020, 136, 50-51.	0.6	0